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Abstract
Gene expression signatures that are predictive of therapeutic response or prognosis are increasingly useful in clinical care;
however, mechanistic (and intuitive) interpretation of expression arrays remains an unmet challenge. Additionally, there is
surprisingly little gene overlap among distinct clinically validated expression signatures. These ‘‘causality challenges’’ hinder
the adoption of signatures as compared to functionally well-characterized single gene biomarkers. To increase the utility of
multi-gene signatures in survival studies, we developed a novel approach to generate ‘‘personal mechanism signatures’’ of
molecular pathways and functions from gene expression arrays. FAIME, the Functional Analysis of Individual Microarray
Expression, computes mechanism scores using rank-weighted gene expression of an individual sample. By comparing head
and neck squamous cell carcinoma (HNSCC) samples with non-tumor control tissues, the precision and recall of deregulated
FAIME-derived mechanisms of pathways and molecular functions are comparable to those produced by conventional
cohort-wide methods (e.g. GSEA). The overlap of ‘‘Oncogenic FAIME Features of HNSCC’’ (statistically significant and
differentially regulated FAIME-derived genesets representing GO functions or KEGG pathways derived from HNSCC tissue)
among three distinct HNSCC datasets (pathways:46%, p,0.001) is more significant than the gene overlap (genes:4%). These
Oncogenic FAIME Features of HNSCC can accurately discriminate tumors from control tissues in two additional HNSCC
datasets (n=35 and 91, F-accuracy=100% and 97%, empirical p,0.001, area under the receiver operating characteristic
curves=99% and 92%), and stratify recurrence-free survival in patients from two independent studies (p=0.0018 and
p=0.032, log-rank). Previous approaches depending on group assignment of individual samples before selecting features or
learning a classifier are limited by design to discrete-class prediction. In contrast, FAIME calculates mechanism profiles for
individual patients without requiring group assignment in validation sets. FAIME is more amenable for clinical deployment
since it translates the gene-level measurements of each given sample into pathways and molecular function profiles that
can be applied to analyze continuous phenotypes in clinical outcome studies (e.g. survival time, tumor volume).
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Introduction
The application of gene signatures to clinical outcome
prediction has become an area of intensive research. In cancer,
expression signatures of poor prognosis [1], recurrence [2],
invasiveness [3], metastasis [4], and therapeutic response [5,6]
have been developed using either data-driven approaches in
clinical trials, or via biologically validated mechanisms found prior
to the clinical trials. However, gene lists of distinct signatures do
not significantly overlap [7,8], even though they paradoxically
occupy a common prognostic space and are similarly efficient in
predicting poor clinical outcomes in new cohorts. These
observations have raised questions about their biologic relevance,
significance and clinical implication [7,8]. New types of mechanism-
anchored gene expression signatures are highly desirable for
personal genomics but are currently unavailable for single sample
prognosis of continuous quantitative phenotypes (e.g. survival
time). Since commercial microarrays are now a mature commer-
cial technology and could become a reliable data source amenable
to clinical practice, we were motivated to investigate the remaining
barriers to their applications in personal genomics.
Aside from differences in computational methods used for
deriving gene expression signatures, several hypotheses have been
postulated to explain the lack of gene overlap and low
reproducibility of the genetic makeup among existing expression
signatures. One explanation is that different genes are merely
PLoS Computational Biology | www.ploscompbiol.org 1 January 2012 | Volume 8 | Issue 1 | e1002350separate aspects of the same groups of molecular pathways or
mechanisms [8,9]. This hypothesis has been examined using the
Kyoto Encyclopedia of Genes and Genomes (KEGG) [10] or Gene
Ontology (GO) [11] to derive functionally related gene-sets as
mechanism-anchored signatures from microarray profiling [12], or
from a priori knowledge and experimental genome-wide expression
data [13]. For conducting such analyses, various analytical and
statistical methods have been developed such as DAVID [14],
GOstat [15], FunCluster [16], FunNet [17], GSEA [18], MGSA
[19], principal component analysis [20], FatiScan [21] and
globaltest [22]. These conventional methods of functional gene-set
analysis (reviewed in [23,24]) have improved our overall ability for
identifying dysregulated mechanisms from gene expression of a
cohort of patients [20,25–29], however they cannot, by design,
provide pathway scores at the single sample level. Thus, their
potential for clinical usage is limited. Developing the capacity to
provide an individualized mechanistic interpretation of analysis
results as they relate to clinical outcomes or treatment strategies, will
greatly enhance the clinical deployment of signatures.
The state-of-art data-driven but rate limiting methods for
generating pathway signatures focus on the coordinated changes in
expression of multiple genes in a pathway experimentally detected
in animal models [30] or on the knock-in or -down of a key
pathway gene in human cells [31,32]. Recently, two types of
knowledge-driven approaches have also been proposed for
generating pathway signatures directly from human tumor
specimens [33] (a) those using the straightforward unsupervised
pathway measures (e.g., mean, median expression of all pathway
gene members) within each sample [28,34], and (b) those
generating pathway scores after performing supervised statistics
requiring sample class assignment (e.g. principal component
analysis, PCA [35–37], CORG ‘‘condition-responsive genes’’
[27], LLR [38]). While the latter set of methods is more accurate
[27], the dependencies between samples preclude their utility for single-
sample prognostication. Furthermore, pathway signatures derived
from these state-of-the-art methods have been validated in
predicting qualitative clinical outcomes, such as complete remission
vs. disease progression. These methods, however, are not designed for
making prediction using continuous clinical measures, such as
recurrence-free survival time [27,38]. Therefore, novel bioinformatics
approaches are required for single-sample assignment of biological
features from gene expression analyses so that the wealth of
seemingly uninterpretable molecular data can be translated into
mechanistic interpretations, which can in turn be utilized for
making therapeutic choices and forecasting clinical outcomes.
We hypothesized that molecular mechanisms delineated from
gene expression deregulation profiles are accessible as genome-
wide measurements of pathways at a single-sample level. Here, we
present a novel methodology, the Functional Analysis of Individual
Microarray Expression (FAIME) that can translate patient
microarray data into pathway and molecular functional profiles
on a single-sample level and can be applied to quantitative
phenotypes of outcome prediction (e.g. survival time, tumor
volume response to therapy). FAIME, by computing statistical
scores on individual patients, retains sample independence within
a cohort and enables subsequent mechanism-level clustering or
signature validation. We demonstrate the potential of FAIME in
personalized genomics using relatively small-size cohorts of Head
and Neck Squamous Cell Cancer (HNSCC) in which FAIME
produces single-patient survival prediction.
Ninety percent of patients with HNSCC will present with
disease that is locoregionally confined and will be considered for
curative intent therapy [39]. However, individual outcome
prognostication is poor because it is based almost entirely on
tumor anatomic location and size [40]. Presently, all patients who
are candidates for curative intent treatment are offered a
multimodality approach that is associated with serious acute
toxicity and long-term dysfunction [41] since there are no reliable
indicators to predict response to therapy. Treatment usually
consists of broadly cytotoxic entities (e.g. radiation, chemothera-
py), and pathobiology based targeted therapies are few [42]. Not
surprisingly, we have shown a strong correlation between response
to induction therapy and survival [42]. Nevertheless, there are
currently no validated pre-treatment classifiers to discriminate the
fraction of patients that will benefit clinically from those who will
not. Therefore, accurate mechanistic derived signatures would
provide valuable prognostic information, the ability to select
patients for appropriately intense treatment, and potentially help
identify novel targets that could be integrated into current therapy.
Results
Figure 1 provides an overview of the experimental design and
the main findings of the study. We first evaluate the robustness of
the within sample FAIME biological mechanism scores (Figure 2)
against those of arithmetic mean of all the gene expression values
in each pathway (Mean-G) and their median (Median-G).
Thereafter, by assigning the clinical group labels to samples, we
compare the deregulated biological mechanisms of FAIME Scores
(Functional FAIME Score of each gene-set for each sample) across
non-tumor control tissue vs. HNSCC tumor samples to those of
Mean-G and Median-G as well as those obtained by CORG, a
method requiring supervised cross-group calculations for scoring
its mechanisms. Taken together, these FAIME-anchored analyses
identify oncogenic pathways and molecular functions robustly
concordant across three head and neck cancer datasets. Subse-
quently, these FAIME derived HNSCC features are used as a
multi-mechanism outcome predictor in a straightforward unsu-
pervised diagnosis classification task using independent datasets to
demonstrate their predictive capabilities at an entry-level task.
Next, the HNSCC FAIME Feature features are used for unsuper-
vised prognostic classifiers with the continuous ‘‘recurrence-free
Author Summary
Clinical utilization of multi-gene expression signatures that
are predictive of therapeutic response has been steadily
increasing, however, interpretation of such results remains
challenging because multi-gene signatures, generated
from analyzing different patient cohorts, tend to be
equally predictive but contain minimal overlap. Whereas
pathway-level analyses of expression arrays show promise
for generating clinically meaningful mechanistic signa-
tures, current approaches do not permit single-patient
based analyses that are independent of cross-group
calculations. To bridge the gap between deterministic
biological mechanisms of single-gene biomarkers and the
statistical predictive power of multi-gene signatures that
are disconnected from mechanisms, we developed FAIME,
a novel method that transforms microarray gene expres-
sion data into individualized patient profiles of molecular
mechanisms. We have validated its capability for predict-
ing clinical outcomes, including cancer patient samples
derived from six different clinical trial cohorts of head and
neck cancers. This method provides opportunities to
harness an untapped resource for personal genomics:
clinical evaluation and testing of individually interpretable
mechanistic profiles derived from gene expression arrays.
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PLoS Computational Biology | www.ploscompbiol.org 2 January 2012 | Volume 8 | Issue 1 | e1002350Figure 1. Outline for conducting HNSCC recurrent-free survival prediction using FAIME-derived mechanism profiles of individual
samples. FAIME-derived individual mechanism profiles are generated from six independent HNSCC gene expression profiles (Figure 2 in the main
manuscript). Then the FAIME Scores are evaluated theoretically for robustness (Figures 3–4, S1) and clinically for new patient diagnosis and survival
prediction (Figures 5, S5, 6, S6).
doi:10.1371/journal.pcbi.1002350.g001
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PLoS Computational Biology | www.ploscompbiol.org 3 January 2012 | Volume 8 | Issue 1 | e1002350Figure 2. Procedure for determining functional/pathway profiles for each sample using microarray expression (FAIME profiles). The
FAIME method is designed to utilize expression arrays of individual samples. Illustrated here with GO terms, this method is also applicable to other
functional gene sets such as KEGG pathways. The FAIME profile is sample independent, thus establishing the foundation for truly individualized
functional profiles independent of a cohort.
doi:10.1371/journal.pcbi.1002350.g002
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of class-based assignment to retain independency between
classified samples. In order to identify single mechanism outcome
predictors, Cox regression analyses are conducted on all individual
FAIME mechanism scores in two datasets and two significant
prognostic mechanisms are identified by meta-analysis. As a
validation, FAIME Scores are compared to the 1
st component of a
Principal Component Analysis for their prognostication.
FAIME increases the robustness of scored pathway
mechanisms (Figures 3, 4, 5, S1, S2)
The FAIME method provides a translation of each sample’s
gene expression to molecular mechanisms (FAIME-score). We
conduct three analyses to compare the robustness of FAIME to
that of previous approaches. We first examine the stability of
FAIME Scores within samples, followed by demonstration of the
reproducibility of deregulated FAIME-derived mechanisms across
three independent HNSCC datasets, and the determination of the
precision and recall of FAIME mechanisms using a ‘‘proxy gold
standard’’ (Methods) as a measure of concordance between
FAIME predictions and other methods.
Stability of FAIME Scores. In Figure S1, FAIME Scores
(first row, panels a–c) are compared to the unsupervised
pathway scoring methods Mean-G and Median-G (rows 2–3,
panels d–i). These analyses are conducted in HNSCC datasets
A, B, and C (Table 1) across three preprocessing conditions of
Figure 3. Reproducibility of molecular pathways and functions derived using FAIME as compared to three conventional enrichment
methods. To establish that FAIME profiles reliably yield functionally overlapping mechanisms across independent datasets for the same phenotype,
we compared the deregulated GO-MF and KEGG FAIME Scores to conventional enrichment studies (hypergeometric enrichment test, GSEA and
CORG). The resultant predictions for each method are plotted in their respective columns for both KEGG (top plots) and GO Molecular Function
(bottom plots) terms. The letters A, B, and C represent the three analyzed HNSCC microarray datasets (Table 1). Each functional analysis method is
independently applied to each dataset and their predicted results are compared in Venn diagrams. FAIME derived features are the most consistent
with 47% to 61% KEGG overlap and 18% to 28% GO-MF overlap between any two datasets. In comparison, the next best method in each case
provided 23% to 41% KEGG overlap (GSEA) and 15% to 19% (Enrichment). These functional overlapping ranges are well above those generally
reported across distinct, yet related, datasets at the gene level [7,9,43]. An FDR of 5% is used for FAIME and enrichment results. GSEA is originally
reported with a FDR,25% [18] and thus we present its cutoff at a FDR=25% where overlap is better than for lower FDRs (we observed fewer
overlapping GSEA results among the three studies at a 5% FDR). CORG does not report data with p-values or FDRs [27] and the absolute cutoffs
presenting the number (n) of resultant KEGG pathways and GO-MF are in a range comparable to that of other methods (Top 10% of KEGG, Top 1% of
GO-MF). The 57 Oncogenic FAIME Features of HNSCC (highlighted in yellow, see Methods) that are common to all three HNSCC datasets shown
above, 33 KEGG terms (46%) and 24 GO terms (17%) obtained by FAIME (Table S1), are used as seeds for validation studies in three other
independent datasets for which the results are shown in Figures 5–6.
doi:10.1371/journal.pcbi.1002350.g003
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PLoS Computational Biology | www.ploscompbiol.org 6 January 2012 | Volume 8 | Issue 1 | e1002350gene expression, each with its corresponding column in Figure
S1. It is obvious that the interquartile spread of FAIME Scores,
calculated within samples, is comparable across samples.
Compared with those of conventional pathway scoring, FAIME
Scores shows higher stability of their pathway scores for every pre-
processing condition with a stable median across samples and a
slight reduction in variation due to the filtering of genes with low
variance (Figure S1). Since FAIME Scores are based on the rank
of gene expression in each sample, they remain stable when using
different gene normalization techniques, and are even applicable
to minimalist log-2 transformed gene expression data devoid of
cross-sample normalization (Figure S1, Panel a, Methods). In
contrast, while MAS5 normalization reduces sample-to-sample
variability, the distribution of pathway scores derived from the
Mean-G or Median-G methods is highly variable across samples.
Additionally, the normality of FAIME Scores within samples,
termed FAIME profiles are comparable to those of log-
transformed gene expression values (Figure S2).
FAIME-derived biological mechanisms are reproducible
across datasets. In Figure 3, the reproducibility of FAIME
deregulated mechanisms in HNSCC datasets A, B and C
(Figure 3, intersection of circles) is compared to that of three
other methods. In the analyses of KEGG pathways [10] and of
Gene Ontology (GO) molecular functions [11], each sample is
assigned to a tumor group or a non-tumor control tissue group.
The four methods are thus compared in the two types of canonical
mechanisms yielding eight groups of Venn Diagrams, each
comprised of three circles, one for each dataset. The intersection
of the circles represents overlapping KEGG pathways (top row)
and GO Molecular functions (Bottom row), where a high
percentage of overlap corresponds to better reproducibility.
Conventional methods for determining deregulated mechanisms
are (i) hypergeometric gene-set enrichment of reported
differentially expressed genes (Enrichment, Text S1 [14,15];
Table 1) and (ii) Gene Set Enrichment Analysis (GSEA, Text S1)
[18]. The Condition-Responsive Genes (CORG, Text S1)
method, which requires supervised group assignment, has been
shown more accurate than Mean-G and Median-G in determining
deregulated pathways [27] and is thus the preferred choice for
evaluation. FAIME obtains the highest reproducibility, yielding 72
predicted GO terms at the union of the three datasets (46%
overlap, empirical p,0.001; Methods). Among these 72
overlapping GO terms, we define 57 Oncogenic FAIME
Features of HNSCC comprising 24 molecular functions and
33 pathways, which are later utilized for FAIME evaluations in
classification tasks. In comparison, all three other methods exhibit
lower reproducibility of pathway predictions across three data sets
(Figure 3). Nevertheless, these methods demonstrate higher
reproducibility at the molecular mechanism space (15–23%
overlap) when compared with 4% direct gene overlap among
the same datasets [7,9,43]. In addition, as shown in Table S1,a
significant portion of the 57 Oncogenic FAIME Features of HNSCC are
also identified by either enrichment, GSEA, or CORG (93%) or
by two out of the three methods (65%). A more thorough
evaluation of FAIME’s concordance with alternative state of the
art methods is also conducted and discussed as below (Figure 4).
FAIME-derived biological mechanisms are concordant
with those obtained by conventional enrichment methods.
Figure 4 illustrates that the biological mechanisms predicted by
deregulated FAIME Scores are reliably concordant with those of
our ‘‘proxy’’ gold standards (conventional Enrichment and GSEA
methods) in each dataset A, B and C. These KEGG pathways and
GO molecular functions previously derived by each of these
methods (Figure 3) are compared across methods in each dataset
individually, rather than across datasets, to yield accuracy scores
(Figure 4). FAIME predicted 60, 46 and 41 KEGG Pathways and
116, 45, and 55 GO Molecular Functions in datasets A, B, and C
respectively totaling 72 and 141 distinct pathways and molecular
function predictions (see high reproducibility of FAIME in
Figure 3). The ‘‘proxy’’ gold standard for each of the precision-
recall curves corresponds to one of the two conventional enrichment
methods, alternated accordingly, allowing us to compare the
accuracy of FAIME predictions to those of one of these methods
(left column of Figure 4). For example, the topmost right area of
Figure 4-Panel (iii) uses the KEGG pathway mechanisms
predicted by enrichment in dataset C as a proxy gold standard to
evaluate the precision and recall of GSEA predictions (blue line) and
thoseofFAIME(redline).SubsequentlyGSEAservesasaproxygold
standard in Figure 4-Panel (vi) to evaluate the predictions from
enrichment (grey) and those of FAIME (red). Overall, the accuracies
of the FAIME derived mechanisms perform at comparable or better
levels than those produced by conventional methods in 10 out of the
12 precision-recall curves, confirming its higher reproducibility in
comparison to the well validated conventional methods. In Figure
S3, we also construct an extensive empirical distribution of KEGG
pathways and GO Molecular Functions predicted by FAIME as a
control to conservatively confirm the significance of the observed
overlap reported in Figure 4.
Oncogenic FAIME Features of HNSCC accurately classify
samples from two independent datasets and provide
biological insights into head and neck cancer (Figure 5,
Table 2). In order to confirm the capability of the Oncogenic
FAIME Features of HNSCC to discriminate HNSCC phenotypes
from non-HNSCC, and to assess the clinical relevance of FAIME
Scores, we conduct a retrospective analysis of two independent
HNSCC datasets. The 57 Oncogenic FAIME Features of HNSCC are
able to classify clinical samples in independent datasets D (n=35),
E (n=91), and GSE9844 (n=38) with zero, four, and three total
misclassifications, respectively (Figure 5, Figure S4).
Furthermore, samples from the two validation datasets can be
accurately classified by the 24 molecular functions from GO (GO-
MF) subset, or by the 33 KEGG pathways subset of the Oncogenic
FAIME Features of HNSCC as shown in Table 2. The classification
power of these Oncogenic FAIME Features of HNSCC is robust as it is
Figure 4. Molecular pathway and function concordance between conventional enrichment methods and differential expression of
FAIME profiles. To establish that FAIME profiles yield relevant GO terms and KEGG pathways, we compared the differential expression of these
profiles to conventional enrichment studies in three independent HNSCC studies (Figure 3, Table 1, Methods). Enrichment and GSEA studies have
been extensively relied upon in biological and clinical studies and are thus alternatively used here as proxy gold standards and positive controls.
FAIME-derived significantly altered KEGG and GO-MF (red) of each dataset are compared to those of GSEA (blue) using Enrichment results as a ‘‘proxy
gold standard’’ (i,ii,iii in both the KEGG pathway and GO-MF panels). Similarly, these FAIME-derived significantly altered KEGG and GO-MF (red) are
also compared to those of Enrichment (grey) using GSEA as the proxy gold standard (iv,v,vi in both panels). The results are reported according to the
number of genes annotated in each KEGG pathway and GO term that are detectable on each respective type of array (Table 1). As shown above,
FAIME’s accuracy is comparable or better than those of the contrasted methods in 10 of the 12 precision-recall curves. Additionally, the high precision
of deregulated FAIME profiles between HNSCC tumors and non-tumor control tissues is illustrated against that of a conservative empirical control
distribution using pooled GSEA results as a ‘‘proxy gold standard’’ in Figure S3.
doi:10.1371/journal.pcbi.1002350.g004
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methods tested (Table 2, Methods). When used jointly, the
FAIME prioritized GO-MF and KEGG pathways are equally
successful in separating HNSCC tumor samples from non-tumor
controls in datasets D and E (Dataset D: n=35, area under the
curve (AUC): AUC=0.99, p=4.3610
27; Dataset E: n=91,
AUC=0.92, p=1.8610
212, Figure 5). The detailed accuracy
metrics show that the FAIME Scores are comparable for
classifying tumor vs. non-tumor control to those of gene-based
classifiers used in head and neck cancer (Table S2).
As shown in both panels I and II of Figure 5, genes in sub-
clusters a and b of up-regulated KEGG pathways and GO
molecular functions are consistently classified together in both
validation datasets D and E by unsupervised methods. The
Figure 5. Significantly altered FAIME-derived Oncogenic FAIME Features of HNSCC accurately classify samples of two independent
validation datasets. In Figure 3, we reported 57 FAIME-derived mechanisms, collectively referred to as the Oncogenic FAIME Features of HNSCC,
that were reproduced in each of the independent HNSCC datasets. These consist of 33 KEGG pathways and 24 GO molecular function terms that were
significantly deregulated between HNSCC tumor samples and non-tumor control tissue in all three HNSCC datasets at an FDR,5% (A, B and C,
Table 1). Here, we demonstrate that the FAIME Scores calculated at the individual sample level in each of the independent validation datasets for
these mechanisms can serve as a ‘‘functional’’ profile rather than a gene profile in sample clustering, a distinctive novel property of FAIME. Panels I
and II respectively show unsupervised average-linkage hierarchical clustering analysis of the Euclidian distances of FAIME Scores for each sample from
the two independent validation datasets, D and E, described in Table 1. As hypothesized, cancer tissue samples are significantly discriminated from
non-tumor control tissue ones in both datasets (Panel I: FAIME-Score=100%, no misclassification, 100 runs of 5-fold cross-validation: AUC=0.99,
p=4.3610
27; Panel II: FAIME-Score=97%, 4 misclassifications among 91 samples, 100 runs of 5-fold cross-validation: AUC=0.92, p=1.8610
212).
Additional conservative empirical p,0.001 are obtained in both panels by permutation resampling of features in AUC calculation. Pathways and
molecular functions in sub-clusters a and b (seen on the left of Panels I, II) are also found similarly clustered in both independent evaluations.
doi:10.1371/journal.pcbi.1002350.g005
Table 1. Descriptive summary of six HNSCC datasets.
Dataset ID in present
study A B C D E F
Dataset name [reference] GSE6631 [61] GSE2379 [62] E-MEXP-44 [63] E-MEXP-44_
hu6800 [63]
JCO2010 [47] GSE686 [48]
Patients and phenotypes
Samples (#) 4 43 8 3 3 3 59 1 * 6 0














P 11 0 0
Median follow-up time
(months)
NA NA NA NA 35 16
Use of each dataset in our study
Identification of Oncogenic











Genomic description of each datasets












Genes in the platform 8,799 8,798 8,799 5,408 19,621 7,329
Genes past filtering
(Methods)
7,764 8,783 8,789 5,349 11,781 4,123
GO molecular functions
associated with filtered gene
2,257 2,407 2,408 2,088 2,402 1,629
KEGG pathways associated
with filtered gene
216 217 217 214 219 209
*71 of these HNSCC samples contained survival information and were included for prognosis validation (Fig. 6) and all samples were included for diagnosis validation
(Fig. 5).
A description of the TNM stage, P53 status, HPV status, smoking status and alcohol intake status is reported in Table S8A–8C.
P: paired samples: each patient contributed two samples (one HNSCC tumor sample and one control non tumor oral tissue).
doi:10.1371/journal.pcbi.1002350.t001
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of their underpinning mechanisms (full list detailed in Table S1).
Cluster a consists of a set of intra- and extra-cellular events such as
cancer pathways, p53 signaling, ECM-receptor interaction and
focal adhesion. Cluster b consists of nuclear events that control
DNA replication, DNA damage repair, and cell cycle progression.
Although each individual mechanism of Clusters a and b is known
for their involvement in the development of human cancer, the
observed coordinated activation of all components within each
cluster is novel. It suggests that oncogenesis requires not only one
pathwayactivationormolecularfunctionenhancement,butalsothe
cooperation among a majority or all of the mechanisms we have
prioritized. Additionally, we have also identified a third cluster –
(Cluster U, Figure 5) which consists of 35 KEGG pathways or GO
molecular functions that exhibits coordinated down regulation in
tumor samples of both validation datasets D and E. They
collectively indicate a reduction in a broad spectrum of biosynthesis
events and metabolic activities (Table S1). There is an increasing
appreciation and understanding of the involvement of metabolism
in cancer. Our observations of the extensive and coordinated
reduction in cellular biosynthesis and metabolism support the
notion that cancer is a ‘‘metabolic disease’’ [44,45].
In summary, the application of the FAIME algorithm to
multiple scales of biological functions (pathways, molecular
functions) demonstrates a novel quantitative approach that is
capable of identifying distinct molecular mechanisms associated
with the onset of cancer, and could thus facilitate the elucidation of
complex biology.
Oncogenic FAIME Features of HNSCC predict recurrence-
free survival (RFS) of new patients (Figures 6, S6)
In addition to its ability to discriminate between the non-tumor
control and HNSCC tumor tissues, the 57 Oncogenic FAIME Features
of HNSCC, as a whole, have significantly higher prognostic power.
They stratify HNSCC samples in two distinct HNSCC datasets (E
and F) into two recurrence-free survival subgroups (log-rank
p=0.0018 and 0.032, dataset E and F, respectively; Figure 6).
This survival analysis exemplifies a distinctive task that FAIME
was designed to accomplish: sample’s mechanisms scores are
calculated without group assignment and thus circumvent the risk
of overtraining. We further validate the prognostic power of
FAIME to predict survival of patients from an additional HNSCC
dataset previously not used in this study, GSE2837 (Log-rank p
=0.049, Kaplan-Meier curve in Figure S5). We then compare
the utility of FAIME-derived scores with other enrichment
methods that also do not require phenotypic group assignment.
In contrast, Enrichment analysis, Mean-G and GSEA scores fail to
provide stratification of patients by RFS time (p.27%, p.7%, and
p.34%; smallest log-rank p reported from dataset E or F;
Enrichment, Mean-G and GSEA respectively; Methods). These
results attest to the utility of FAIME for learning predictive
mechanism patterns from gene expression in pursuance of
quantitative phenotypes such as survival analysis. In order to
compare the prognostic power of FAIME to other prognosticators
of HNSCC, we note that for dataset E in this study, the authors
report a non-statistically significant trend for HPV+ HNC patients
to have better survival outcomes when compared to HPV- HNC
patients (HNSCCs classified according to Pyeon HPV geneset
[46]: p=0.09 and p=0.33 for two independent datasets; HNSCCs
classified HPV+/2 by p16 IHC: p=0.20 and p=0.52 for two
independent datasets). In contrast, we show that when FAIME is
run on this dataset, we obtain a significant prognostic indicator for
survival outcome for datasets E, F, and GSE2837 (p=0.0018,
p=0.032, p=0.049, respectively) in Figure 6 and Figure S5.
We next investigate if these FAIME-derived patterns could
recapitulate known biological and pathophysiological knowledge.
Table 2. Robustness of the accuracy of FAIME-derived Oncogenic FAIME Features of HNSCC in separating tumor from control tissue
samples.
Measure of Accuracy R FAIME-Score
Oncogenic FAIME Features of HNSCC R 24 Molecular Functions (GO-MF)
1 33 Pathways (KEGG)
1
Clinical Datasets (see Table 1: D, E) R DED E
Unsupervised Clustering method* Software
Ward linkage of Euclidean distances Bioconductor package (amap) 100% 98% 96% 97%
Average linkage of Euclidean distances dChip 100% 98% 98% 97%
Centroid linkage of Correlation distances, with
column standardization for sample clustering
dChip 100% 98% 98% 96%
Centroid linkage of Correlation distances dChip 100% 98% 98% 96%
Partitioning Around Medoids (PAM, k=2) Bioconductor package (cluster) 100% 96% 96% 96%
57 deregulated Oncogenic FAIME Features of HNSCC were reproducibly derived by FAIME in the three independent datasets (A, B, and C; Figure 3, Table 1) and
shown that they can jointly classify non-tumor control tissue from HNSCC tumors in two validation datasets (D and E; Figure 5, Table 1). This table also illustrates that
the constituents of the HNSCC Oncogenic FAIME Features of HNSCC (columns), the 24 GO Molecular Functions and the 33 KEGG pathways, were also independently
accurate in separating tumor from control tissue samples in the validation datasets. Furthermore, we report that this predictive accuracy is robustly reproduced using
five different unsupervised clustering algorithms (rows below). In the remainder of the manuscript, these Oncogenic FAIME Features of HNSCC are pooled together for
prognosis predictions in Figures 5–6.
*Default parameters of the clustering algorithms were used unless otherwise specified. After applying each clustering method to the FPHNSCC,s, the first two-way
partition of samples was used to determine two classes compared with the tumor sample group and the control group of two independent datasets D and E (Table 1).
False positive results were control samples misclassified within the tumor sample cluster and false negative results were tumor samples classified as control tissue. The
FAIME-Score accuracy for separating 23 HNSCC tumors from 13 control samples of the E-MEXP44_hu6800 array was calculated as F~2: precision:recall
precisionzrecall
.
1: GO-MF terms and KEGG pathways were not included if there were no mapped genes that passed the IQR filter in this validation dataset.
Legend: FPHNSCC,s is defined as the subset of the Functional FAIME Profile consisting of the 57 Oncogenic FAIME Features of HNSCC deregulated in the initial datasets A,
Ba n dC( Equation 4, Methods, Figure 3); GO: Gene ontology, MF: molecular function.
doi:10.1371/journal.pcbi.1002350.t002
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HNSCC significantly overlap with the KEGG pathways and GO-
MF that can be derived by enrichment of the 31 genes (54 probes)
associated with disease-specific survival in a study by Thurlow et
al. [47]. In the second study by Perou and colleagues, a set of 582
deregulated genes has classified HNSCC into four ‘‘intrinsic’’
groups (I–IV), of which some combinations are associated with
poorer recurrence-free survival [48] (dataset F, Table 1).
Importantly, FAIME can recapitulate at the mechanism level this
molecular classification: by producing four groups using an
unsupervised method, the 57 Oncogenic FAIME Features of HNSCC
are enriched in the four original ‘‘intrinsic’’ groups of Perou’s
molecular classification of HNSCC samples (p=0.0031, Meth-
ods, Dataset F, Fisher’s Exact Test on a 464 contingency table).
It has been demonstrated that some multi-gene expression
signature classifiers, derived from comparisons made between the
cancer and control tissues, can provide both diagnostic stratifica-
tion of clinical tumor samples as expected, as well as prognostic
prediction of clinical outcomes, such as RFS or overall survival
across patients within a clinical cohort [47,48]. However, to our
knowledge this is the first mechanism-level predictor, generated
from gene expression changes between the cancer and control
tissues, that possess both diagnostic and prognostic power at the
level of each individual clinical sample without requiring group
assignment in validation sets. These observations also indicate that
common molecular mechanisms may underlie oncogenesis and
disease recurrence. Therefore, therapeutic targeting of such
common mechanisms may have potential clinical benefits of
effective local control of primary tumors, and at the same time,
preventing disease recurrence.
FAIME-derived single mechanisms also predict
recurrence-free survival (RFS)
In order to prioritize other potential RFS mechanisms and to
further demonstrate the utility of FAIME Scores for the study of
quantitative phenotypes (e.g. RFS), we conduct a Cox regression
analysis of recurrence-free survival time for each of the 208
KEGG pathways and 956 GO terms for which a FAIME Score
could be computed in datasets E and F with four or more genes
per mechanism (Methods, Table 1). Two significant mechanism
genesets can each be considered as a ‘‘single mechanism’’
prognostic predictor of RFS for future clinical validation: (i)
[hsa04210], and (ii) receptor signaling complex scaffold activity
[GO:0030159] (p=0.0026 and 0.0034 respectively; Bonferroni-
adjusted meta-analysis across Datasets E and F of the Cox
regressions Table S3, Methods). Since disease recurrence is also
a predictor of RFS, FAIME Scores of these pre-treatment samples
are also significantly decreased in patients with rapid onset of
disease recurrence in both datasets E and F (Table S3, Mann-
Whitney test).
As a proof-of-concept study we focus on the topmost candidate
RFS mechanism, and conduct a Principal Component Analysis
(PCA) of datasets E and F for the prioritized KEGG apoptosis
geneset (KEGG pathway [hsa04210] containing known genes
associated with apoptosis pathways annotated in humans) since
PCA can provide an unbiased approach to derive a metric
representing the highest biological variation across samples that
can be associated with the biological mechanism(s) responsible for
this variation. As expected, PCA’s first component of the KEGG
apoptosis geneset gene expression is also a predictor of deregulated
RFS (Cox regression p=0.0027 and 0.044, Datasets E and F).
Figure 6. Oncogenic FAIME Features of HNSCC stratify recurrence-free survival (Kaplan-Meier) of tumor samples in two independent
datasets. The 57 Oncogenic FAIME Features of HNSCC discriminate between HNSCC and non-tumor control tissue at 5% FDR, in each dataset A, B
and C, which are independently validated in both datasets D and E (Figure 5). Here, the Oncogenic FAIME Features of HNSCC are analyzed in tumor
samples and shown to be predictive of recurrence-free survival as shown in independent datasets E and F (Panels a–b). Oncogenic FAIME Features of
HNSCC of each patient tumor sample in datasets E and F are used as a whole with an unsupervised partitioning method to split patients into two
groups for which the Cox proportional hazard and Kaplan-Meier curves are subsequently calculated to evaluate the prediction of survival (Methods).
doi:10.1371/journal.pcbi.1002350.g006
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KEGG apoptosis geneset are correlated (Spearman p=1.3610
28
and 0.047 in datasets E and F respectively, Table S3). The
detailed list of genes of the KEGG canonical apoptosis geneset is
listed in Table S4. Additionally, we show that FAIME Scores of
the KEGG apoptosis geneset are significantly increased in the
HNSCC tissues of patients with no evidence of disease recurrence
as compared to those of patients with recurrence within both
datasets E and F (p=0.0015 and p=00051, respectively, Figure
S7). Consistent with these results, HNSCC patients are treated
with radiotherapy and conventional chemotherapy regimens that
should subsequently induce apoptosis through DNA damage cell
cycle checkpoints. Therapy-resistant tumors are more likely to
recur early, which is consistent with the observed reduction in the
FAIME apoptosis geneset score in patient samples with disease
recurrence reflecting a reduced capability of checkpoints to elicit
an apoptotic response to therapy-induced DNA damage. The
correlation of reduced level of expression of the KEGG apoptosis
geneset reported by the FAIME Score in patients with more rapid
onset of disease recurrence may reflect aberrant cell cycle
checkpoint and DNA damage repair regulation leading to an
enhanced survival of HNSCC cancer cells in recurrent patients.
This computational FAIME method identifies deregulated gene-
sets associated to mechanisms, and after validation of the FAIME
Scores in a prospective study, we will also pursue to validate the
deregulation of mechanisms associated to this genesets, such as the
apoptosis geneset. Since a pathway-level classifier can be
considered as a significant predictor based on the ensemble effect
of its constituent gene in a patient, these same genes need not be
consistently deregulated in each patient. In other words, the effect
is measured at the mechanism level.
Discussion
FAIME Scores are designed to identify molecular mechanisms
whose constituent genes are predominantly up- or down-deregulated,
but not both together. We thus regard the present design as a
stepping-stone that improves clinical and biological interpretability by
reducing the number of features as compared to gene expression
signature classifiers, and by obtaining increased statistical power that
allows for the inclusion or refutation of each mechanism at the single
patient level. Alternatively, the gene expression changes in both
directions could be assessed indiscriminately so that subtle changes in
molecular mechanisms due to the opposite effect of inhibitor and
activator genes of a given pathway can also be identified. Better still,
pathway annotations that indicate gene inhibitors and gene
enhancers of signals could be pooled together according to the
logical direction of the biological significance in the pathway.
In principle, FAIME Scores are applicable to other scales of
individual quantitative genomic data annotated into genesets from
a knowledgebase, for example, from single protein activity
measurements. For these extensions, alternative decreasing
weights and their effects on FAIME Score need to be discussed.
In this manuscript, the weighting strategy used by the FAIME
Score is a rank based decreasing from the highest expressed genes
to non-expressed genes in individual samples. We chose the
weights to decay exponentially based on previous modeling of
expression data we conducted [49,50] (Equation 1), arguably
future studies may explore alternate models, particularly for
different types of genomic data that have not been modeled.
Currently, the effort required for interpreting the biological
significance of individual genes in expression signature classifiers is
challenging. As shown by Bild et al, mechanism-based predictors
can bring us one step closer to guiding targeted therapies by using
oncogenic pathways derived from cellular experiments [35].
Additional improvements are required to translate FAIME
technology for its use in a clinical setting. Specifically, we intend
to prospectively validate the capability of Oncogenic FAIME Features of
HNSCC to predict survival in a cohort of HNSCC patients treated
with a) cytotoxic chemotherapy (e.g. induction chemotherapy), b)
radiation, and/or c) an EGFR inhibitor. Future studies will test
FAIME’s ability to distinguish between patient tumor subtypes: 1)
HPV positive vs. HPV negative, 2) low risk for failure vs. high risk
for failure to therapy, and 3) emerging genetic drivers of HNSCC
(ongoing TCGA cancer genome atlas effort in head and neck
cancer). Here, we describe the development and evaluation of
FAIME, a computational rather than biological approach designed
specifically with the intent for enabling clinicians to functionally
interpret individual patient samples using quantitative phenotypes.
Additional improvements are required to translate this technology
into clinical care, such as the ability to directly interpret a single
microarray without cross sample normalization. For example, the
‘‘Gene Expression Barcode’’ relies on a reference standard to
interpret single array gene expression [51,52]. Furthermore, we and
others have shown analytical approaches that do not require a
referencestandard nor cross-sample normalizationtointerpret virus
genesets at the single pan-microbial array level [53,54] whose
clinicalutilityhasbeendocumentedinsomecase reportsandstudies
[55,56]. In principle, these approaches could be used jointly with
FAIME to improve the efficiency of single sample analyses. We
note, however, that our analysis of differential gene expression and
corresponding mechanisms of head and neck cancer may be
complicated by the process of ‘‘field cancerization,’’ whereby an
area of epithelium is preconditioned by a carcinogenic agent, and
carcinomamay subsequently arise from multifocal areas [57]. Thus,
future expression analyses should scrutinize obtaining non-tumor
tissue controls as to avoid the effect of ‘‘field cancerization’’ by using
matched controls. Additionally, testing datasets analyzed in this
study obtained gene expression data from Affymetrix and Agilent
platforms, confirming that our approach is amenable to different
gene expression platforms and future studies may utilize additional
tissue arrays.
Indeed, we recognized that different extraction methods of the
tissue, including laser microdissection, could contribute to generat-
ing different classifiers. Conceivably, classifiers built from non-laser
microdissected data may reveal important genetic signatures
encompassing tumor interactions with surrounding stromal cells,
but more precise methods are needed to isolate these cells. We note
that all tumor samples in the three training datasets and testing
datasets D, GSE2837, and GSE9844 contain at least 70% tumor
cells (Table S5). We provide in Figure S4 showing the validation
of the Oncogenic FAIME Features of HNSCC in an independent laser
microdissected tumor and non-tumor tissue dataset GSE9844 with
a positive predictive value=92% (3 misclassifications) and p=0.04
(rank statistics, 100 feature permutations, hierarchical clustering
analysis using R). Furthermore, in our comparison of laser
microdissected tumor tissue with non-tumor control tissue
(GSE9844), we identified 751 out of 2,699 significantly deregulated
FAIME Scores that were calculated using genesets of mechanisms
(q-value,0.05, z-test adjusted for multiple comparisons). Of the 57
Oncogenic FAIME Features of HNSCC (57 GO and KEGG genesets),
47 were confirmed among these 751 and are deregulated in the
same upordown directionsoriginallyobserved indatasetsA,B,and
C( p,10e-16, enrichment study using Fischer Exact Test, Table
S6). Furthermore, we found that Oncogenic FAIME Features of HNSCC
were able to accurately classify laser microdissected tumor tissues
from non-tumor tissues (GSE9844, n=38, 3 misclassifications using
conventional unsupervised two-way hierarchical clustering). We
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microdissected tumor tissue is not only feasible, but is also
concordant with results from non-laser microdissected tissue
datasets in this study.
Conventional pathway level classifiers obtained from in vitro/in
vivo biological experiments are predetermined and rate limiting for
discovering multiple oncogenic pathways or mechanisms, as each
require their own biased experimentation [31,32,35,58]. In
contrast, in silico knowledge driven approaches are high throughput
and can analyze, in an unbiased manner, a larger number of
biological mechanisms. Improved reproducibility is achieved with
machine-learned mechanism-based predictors that use group
assignment (e.g. CORG [27], LLR [38]), as compared to
mechanism predictors derived from the straightforward scoring
methods such as Mean-G and Median-G. While ‘‘group assign-
ment’’-dependentmethodsareeffectiveinimputingmechanismsfor
qualitative phenotypes, they are not designed for imputing from a
quantitative phenotype. We have designed FAIME to address this
challenge. We show that a FAIME-derived predictor composed of
Oncogenic FAIME Features of HNSCC can withstand regression
analyses of continuous survival time data to predict disease free
survival. Beyond predictor construction, we have shown that
FAIME-derived mechanisms controlled for multiple comparisons
can be retained independently as single mechanism classifiers. We
also demonstrate that Oncogenic FAIME Features of HNSCC can
classify reproducibly head and neck cancer survival, and have the
potential for new knowledge discovery. Furthermore, this approach
can conservatively prioritize three classifiers based on a single
mechanism classifier for experimental or clinical follow-up valida-
tion.FuturestudieswilladdressFAIME’sapplicabilitytoavarietyof
other cancers and tissue-oriented diseases, including oncogenic
FAIME Scores of colon cancer metastases progression and of
prostate cancer recurrence that are underway.
Survival in HNSCC is currently assessed with a mix of TNM
staging and biomarker status, such as Human Papilloma Virus
(HPV). The utility of gene expression signatures in HNSCC lags
behind better suited ones developed in other cancers, such as breast
cancer, where expression classifiers are commercially available (e.g.
MammaPrintH microarray [59]. Table S2 shows that the accuracy
ofOncogenicFAIME FeaturesofHNSCC to classifytumor vs. non-tumor
tissue is comparable to or outperforms those of gene expression
classifier signatures in head and neck cancers from the respective
papers. However, gene expression signatures are not utilized in
clinical settings for head and neck cancers, in part because of their
lack of genetic overlap. Deregulated GO and KEGG FAIME Scores
have shown a significantly higher overlap between datasets
(Figure 2) than deregulated genes between these datasets (Legend
of Figure 2). This reproducibility of FAIME Scores addresses a
crucial problem of gene-level expression signatures illustrated by Dr.
Joan Massague ´ in an editorial of the New England Journal of
Medicine [60]. In summary, Massague ´ points out that gene
signatures have surprisingly very little overlap when designed in
different cohorts, even though they may be equally predictive of the
same clinical outcome in these cohorts. In the future, the survival
prediction of FAIME Scores is expected to help identify patients,
among those for which traditional clinical indicators are inadequate,
at high risk of treatment failure that would benefit from more
intensive therapy.
Methods
Data preparation and databases
Eight gene expression microarray datasets pertaining to
HNSCC are used: three for learning expression patterns and for
demonstrating concordances of FAIME (Table 1: datasets A–C
[61–63]), while five other datasets are used for validation (Table 1:
datasets D–F [63,47,48], Figure S4 laser-microdissected dataset
GSE9844 [64] and Figure S5 dataset GSE2837 [65]). The
samples of the validation datasets do not overlap with the learning
datasets. We define non-tumor control samples as (i) samples
from an independent, non-smoker individual with no history of
HNSCC, (ii) paired samples from a distant uninvolved site in
patient with HNC (.3 cm or contralateral), and (iii) paired
samples from the margin of a tumor. For each of these three types
of control samples, Table S7 provides the percentage of samples
per anatomical location. Several of the non-tumor tissue control
samples are enriched specifically for epithelial cells (datasets B, E,
F, GSE2837, GSE9844), the cell type of origin for head and neck
cancer cells, while other non-tumor controls were extracted from
mucosae tissues (datasets A, C and D). Additionally, a description
of the TNM stage, P53 status, HPV status, smoking status and
alcohol intake status is reported in Table S8A–8C.
Pre-processing of gene-expression profiles. The gene
expression CEL files of the GEO and ArrayExpress datasets A–
Do fTable 1 are normalized by the MAS5 method using the
Bioconductor package affy. The normalized gene expression
profiles of the larger datasets E and F (Table 1) are directly
downloaded from GEO and all measurements are log2-
transformed. Probe-set filtering. Since probe-sets with little
variability across samples provide no discriminatory power [66],
the probe-set of a gene with the largest inter-quartile range (IQR)
of gene expression is retained for this gene in the study after
removing genes for which the average log2 expression across
samples is negative (Table 1). As such, filtering procedure focuses
on the most informative genes and can control for multiple probe-
sets per gene bias.
Microarray platform annotation was downloaded from
the GEO website (http://www.ncbi.nlm.nih.gov/geo/) for the
GSE686 dataset using an Agilent platform. For the other datasets
using Affymetrix platforms, the annotations are derived from the
Bioconductor package hgu95av2.db_2.3.5, hu6800.db_2.3.5 and
org.Hs.ef.db_2.3.6.
Gene Ontology (GO) annotations for human genes were
downloaded from NCBI (ftp://ftp.ncbi.nlm.nih.gov/gene/DA-
TA/gene2go.gz) on December 11, 2009. The GO Molecular
Functions (GO-MFs) with more than 3 annotated genes are
studied.
KEGG pathway annotations are imbedded in Bioconductor
database KEGG.db version 2.3.5. This map is based on data
provided by: KEGG GENOME (ftp://ftp.genome.jp/pub/kegg/
genomes) with a date stamp of September 16, 2009. The KEGG
pathways with more than 3 annotated genes are studied.
FAIME profile (Figure 2)
Computes the normalized centroid of each mechanism-
anchored gene-set based on the rank-weighted gene
expression of a sample. The FAIME profile is designed to
utilize expression arrays of individual samples for establishing the
basis of generating individualized functional profiles (Figure 2)
that can be directly used to identify gene-sets that separate patients
into clinical groups or other clinically useful continuous variables
such as survival time or tumor volume. The following section
describes the steps used to calculate the ‘‘functional’’ profile of
FAIME (FAIME profile). For brevity, we illustrate mechanism-
based FAIME Profiles in the following equations using GO terms,
while KEGG-annotated FAIME profiles are calculated similarly.
To quantitatively assign a mechanism’s ‘‘expression deregula-
tion’’ via its gene members, whose expression is measured in a
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descending order according to their expression levels, and then an
exponential decreasing weight (w) is assigned to the ordered genes
(Equation 1). The resultant weighted expression values are used to
prioritize relatively highly expressed genes as in the first step of
Bioconductor package OrderedList [49,67].Specifically,let rg,sbethe
expression rank for each gene g M G in a sample s,l e t| G| be the
total number of distinct genes in the array and the weight assigned





A Normalized Centroid (NC) is defined as the uni-dimensional
average of the weighted expression values of a gene-set.
Specifically, the sum of the weighted expression of gene element
in a gene-set is normalized according to its cardinality. For every
GO term, there is a gene-set GOi in which genes satisfy g M GOi
and a complement gene-set (G/GOi) comprised of all available
genes in the array that are not annotated to this GO term. Thus
we calculate the normalized centroid of each gene-set GOi in each













where G=GOi~fg : g6[GOi \g[Gg:
Furthermore, the Functional FAIME Score (F in equations)o f
each gene-set of a GO term is calculated in every sample as the
difference between the normalized centroid of its gene-set and that
of its complement gene-set (Equation 3). We define functional
scores as functional biological mechanisms of the gene-set
associated with a GO term in a given example.
FGOi,s~F(GOi,s)~NC(GOi,s){NC(G=GOi,s): ð3Þ
Equation 4 calculates for a sample s, the FAIME Profile
‘‘FPs’’ defined as the set of all of FAIME FAIME-Scores of sample
s, FGOi,s, assigned to every GO term.
FPs~ FGO1,s,    , FGOi,s,    , FGOn,s
no
, ð4Þ
where n is the total number of GO terms.
In this way, patient-specific FAIME profiles of KEGG and GO
are generated for each sample (Figure 2). Each sample has a
continuous effective value for each category term which is the
group difference between the genes annotated by the KEGG or
GO terms and their individual complementary set of genes [50].
FAIME Profiles of HNSCC microarray data. For each
microarray dataset (Table 1), gene expression is transformed into
FAIME profiles of KEGG pathways and GO molecular functions
for each individual sample in all datasets (A–F).
FAIME scoring and profiling are implemented using open
source R software (Text S2).
FAIME score stability, robustness and reproducibility
evaluations
Stability and robustness of FAIME scores with and
without cross-sample normalization and gene filtering
(Tables 1–2, Figure S1). To evaluate the stability of FAIME-
derived pathway scores (Eq.3) regardless of the gene expression
preprocessing methods, a FAIME Score distribution for each
sample is illustrated using boxplots (Figure S1). These boxplots
present the median, 25% to 75% interval of distribution (box) and
the 1.5 inter-quartile ranges (dashed vertical whiskers) calculated
using R package graphics. Specifically, the FAIME-derived
pathway scores are applied to (i) minimalist within-sample log2
transformation, (ii) within- and across-sample normalization using
MAS5 method [68], and (iii) MAS5 normalization with gene
filtering (see Data preparation and databases). Using the
‘‘affy’’ package [68] of the Bioconductor software [69], the
Affymetrix’s MAS 5.0 normalization of expression measurements
is implemented using the ‘‘mas5’’ function with default parameters,
and the within-sample normalization is conducted using the
‘‘expresso’’ function without cross-sample normalization. Similarly
under each of above three pre-processing conditions, the arithmetic
mean of all the Gene expression values in each pathway (Mean-G)
and their median (Median-G) are also applied in each sample
according to previously detailed methods [34]. The resultant
pathway boxplots are also presented in Figure S1 for comparison
to those of FAIME.
Functional and pathway reproducibility of significantly
deregulated FAIME molecular functions and pathways in
HNSCC as compared to those of conventional enrichment
methods (Figure 3). Before conducting evaluation of novel
approaches, such as diagnosis and prognosis based on sample-level
FAIME-derived profiles, we first demonstrate how well FAIME
compares with traditional enrichment methods in identifying
altered molecular mechanisms between HNSCC tumors and non-
tumor control tissues in three independent HNSCC datasets
(Table 1, datasets A–C). We describe below the overlap among
FAIME-derived differentially altered mechanisms, as well as those
generated by three conventional approaches: (i) hypergeometric
enrichment analysis, (ii) GSEA, and (iii) CORG.
Three conventional approaches, hypergeometric enrich-
ment analysis [50,70,71], GSEA [18,23], and CORG [27] are
applied to the same three datasets (A,B,C, Table 1) to detect
KEGG and GO-MF terms (Text S1). The KEGG pathway and
GO-MF overlap is illustrated as Venn diagrams for each approach
(Figure 3).
Oncogenic FAIME Features of HNSCC. FAIME-derived
KEGG and GO-MF terms significantly associated with HNSCC
malignant transformation are obtained by comparing the FGOi,s
(Equation 3) of each KEGG or GO gene-set between the tumor
and control tissue groups in each of the three HNSCC datasets
(A,B,C, Table 1) using a Z-test (paired or unpaired according to
the nature of the HNSCC dataset). Before using a Z-test, we also
confirm in three HNSCC datasets that FAIME Scores of GO-MFs
derived from Equation 3 meet the same criteria of the normality
test as conventional gene profiling (Figure S2). To estimate the
statistical significance of FAIME-derived mechanisms, a
permutation-based test is applied 1000 times for each dataset
(resampling sample phenotype assignment), with each application
preserves the intra-subcategory relationships of the KEGG and
GO terms inherited from the genes. Then, empirical p-values of
the observed statistics are calculated from the null distribution
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adjustments for multiple comparisons are done using the
Benjamini and Yekutieli method to control for the FDR [73] at
#5%. The resulting deregulated GO molecular functions are
further filtered by the GO-Module approach we developed [74],
which removes reported false positive p-values inherited in the GO
hierarchy [75,76] as we previously described [50]. Briefly, GO-
Module identifies the representative node for each region that has
the smallest adjusted p-value when compared to its graphical
contiguous neighbors.
The reproducibility of deregulated FAIME-derived KEGG
pathways and GO-MFs between HNSCC tumor samples and
non-tumor control tissues is measured by the overlap of the
significant mechanisms among the three distinct datasets (Onco-
genic FAIME Features of HNSCC) as illustrated in the Venn
diagrams of Figure 3. The statistical significance of these Oncogenic
FAIME Features of HNSCC is estimated empirically by randomly
resampling, without replacement, the same number of predicted
KEGG/GO terms from each dataset 1,000 times, and at each
time of sampling, the potential 3-way overlap is measured.
Additionally, hypergeometric enrichment of GSE6631 expression
profile is used as a gold standard (data not shown), in which
significantly deregulated FAIME-derived molecular functions and
pathways in HNSCC are robustly and consistently present,
independent of changing parameters used in analyses such as (i)
within array normalization vs. the conventional within and across
array normalization (ii) with or without gene-filtering, iii) using a
parametric Z test or a non-parametric U-test, and (iv) GO gene
annotations downloaded from the NCBI vs. those provided by
Bioconductor GO2ALL. Furthermore, to demonstrate that mecha-
nism overlap as measured by gene-sets is higher than conventional
gene overlap, we compare FAIME-derived GO-MF or KEGG
overlap across datasets to the overlap of the original published
gene signatures [61–63].
Methods of evaluation. This section describes four
classification evaluations: (a) the concordance of FAIME-derived
molecular mechanisms with results obtained by three conventional
methods (Figure 4), (b–c) the clustering of FAIME-derived
profiles of individual samples taken from additional independent
datasets for diagnostic sample classification and recurrence-free
survival prediction (Figures 5–6), and (d) the validation of
recurrence-free survival prediction of FAIME profiles using
independent samples.
Concordance between deregulated FAIME-derived
molecular functions and pathways in HNSCC and those
obtained by conventional enrichment methods (Figure 4)
In order to objectively assess the accuracy of the significantly
deregulated GO-MF and KEGG pathways identified in each of
the three HNSCC datasets identified by FAIME (Figure 3), a
gold standard comprising the true KEGG and GO terms should
be used. However, such a gold standard does not exist and
published enrichment studies that generated large lists of
candidate GO terms and KEGG pathways cannot be thoroughly
validated experimentally in their entirety because of the rate
limiting nature and cost of such an endeavor. Nonetheless, since a
sufficient subset of individual predictions of deregulated molecular
functions and pathways from these enrichment studies have been
confirmed experimentally, we proceed in using conventional
enrichment methods as ‘‘proxy-gold standards’’. Specifically,
GSEA and the hypergeometric enrichments are alternating as
proxy-gold standards and as positive controls. These enrichment
methods and FAIME are applied to three distinct datasets as
described in Stability and Robustness of FAIME Scores
with and without cross-sample normalization and gene
filtering (Table 1, datasets A–C). The union of all prioritized
GO-MF or KEGG pathways of GSEA or of the hypergeometric
analysis illustrated in Figure 3 is alternatively used as a proxy gold
standard. Precision and recall is thus calculated for the FAIME
results of a specific dataset and that of the remaining conventional
method not used to generate the proxy gold standard. The latter
serves as a positive conventional control to compare the accuracy
of FAIME-derived results.
Evaluation of the utility of Oncogenic FAIME Features of
HNSCC for diagnostic sample clustering using two
additional and independent validation datasets (Figure 5).
The 57 Oncogenic FAIME Features of HNSCC, the 33 GO-MFs and
24 KEGG pathways defined in Figure 3, serve as seed features to
be evaluated in diagnostic validation studies conducted in two
independent datasets. To this end, the subset of the Functional
FAIME profiles (FP; Equation 4) comprising these 57 Oncogenic
FAIME Features of HNSCC (FPHNSCC,s) are calculated individually
for each sample s in the validation datasets (Table 1: D and E).
Then unsupervised hierarchical clustering of the FPHNSCC,s is
conducted in each dataset separately as illustrated in Figure 5,
where the gene-sets of KEGG pathways and GO-MF have at least
3 genes expressed in the independent validation datasets. As we
proceed in clustering tumors samples separately from non-tumor
control samples we further evaluate whether the accuracy of the
results is dependent on the clustering method. The robustness of
the Oncogenic FAIME Features of HNSCC in separating tumor
samples from control tissues is demonstrated by measuring the
consistency of the accuracy produced when using different
unsupervised clustering approaches (Table 2). Table 2 shows
the accuracy of the subcomponents of the Oncogenic FAIME Features
of HNSCC taken independently, each consisting of GO-MFs or
KEGG pathways. The FAIME-Score is used to measure the
accuracy and recall of unsupervised sample clustering as compared
to their actual clinical condition. In the results section, simulated
FAIME-Scores are calculated using the profiles of randomly
sampled KEGG/GO terms with the same size as our Oncogenic
FAIME Features of HNSCC (n=57) to cluster samples in the
validation datasets. An empirical p-value is accordingly calculated
after running 1000 simulations (Figure 5). Additionally, a
measure of the area under the curve (AUC) of receiver operator
characteristics curve (ROC) is empirically calculated using 100
runs of a five-fold cross-validation [24,64]. Using the FAIME
methods as reported in Figure S1, we identified 63 deregulated
mechanisms between HNSCC tumors and control tissue with an
FDR,5% in both datasets E and F. 39 of these 63 mechanisms
recapitulate the 57 Oncogenic FAIME Features of HNSCC that are
derived at an FDR,5% in datasets A, B and C (p=3 610
242,
Fisher’s Exact Text; n=2758 mechanisms, FDR,5% in datasets
E&F for 63 mechanisms).
Proof of concept: utility of FAIME-derived Oncogenic
FAIME Features of HNSCC for predicting patient survival in
two independent validation datasets (Figure 6). An
additional experiment is conducted to confirm that FAIME-
derived HNSCC features are implicated in patient survival. This
assumption of the Oncogenic FAIME Features of HNSCC ’ prognostic
power is based on the fact that mechanisms involved in
oncogenicity are correlated with patient survival [77,78]. In
order to generate the validation studies of survival shown in
Figure 6, the subset of the Functional FAIME profiles consisting
of the Oncogenic FAIME Features of HNSCC (FPHNSCC,s, FAIME
Score Stability, Robustness and Reproducibility Evaluations) are
calculated on each tumor sample that has associated patient
survival data in the independent datasets E and F separately
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dataset, patients are divided into two or three groups using the
Bioconductor package cluster by the unsupervised partitioning
method called ‘‘clustering large applications’’ (CLARA) whose
robustness has also been previously shown [79,80]. Subsequently,
Cox proportional hazard regression analyses with censored
endpoints are carried out and Kaplan-Meier survival curves are
generated by the Bioconductor package survival for the predicted
clustering of patient samples. The log-rank p-value is used to
evaluate the prognosis of this sample clustering. Note that in
dataset E, duplicate samples are available for 6 patients leading to
two FPHNSCC,s. Thus to avoid duplicate dependent measures for
each patient, the average expression of the FPHNSCC,s is used when
partitioning with CLARA.
Validated FAIME Scores’ ability to reproduce a
molecular classification of HNSCC (Figure S6). Two
validation studies are conducted. First, we investigate if these
FAIME-derived patterns can recapitulate known biological and
pathophysiological knowledge. This is done by comparing the
Oncogenic FAIME Features of HNSCC we derived with those of a
gold standard: the mechanisms that are significantly enriched
among genes associated with disease-specific survival [47]
(Figure S6). We next use FAIME Scores to recapitulate
Perou’s molecular classification of four ‘‘intrinsic’’ HNSCC
sample groups in dataset F [48]. The FAIME-derived profiles
are used to stratify HNSCC tumor samples of dataset F in an
unsupervised manner into four groups by applying the CLARA
algorithm with default parameters on the 57 Oncogenic FAIME
Features of HNSCC. The R software’s Fisher’s Exact Test is
employed to evaluate the overall enrichment in the resultant 464
contingency table consisting of the four FAIME-derived groups of
samples and the four HNSCC molecular mechanism groups
published by Perou and colleagues.
FAIME-derived Recurrence-Free Survival (RFS) prognostic
mechanisms using Cox proportional hazards (Table S3)
The FAIME-derived mechanism scores of the 208 measurable
KEGG pathways and 956 GO-MF terms with more than 3 gene
members are calculated for each of the 71 patient samples in
dataset E and the 60 patient samples in dataset F. In each dataset,
the RFS prognostic power is assessed using a Cox proportional
hazards regression with the Bioconductor package survival (default
parameters for censured data) [81]. In each dataset, a cohort-
specific prognostic p-value can thus be calculated for each of these
1,164 mechanisms using the Cox-regression analysis (Bioconduc-
tor package survival). A meta-analysis of these Cox-regression p-
values is then performed using the Stouffer Z-transform method
[82] that produces a joint p-value for each mechanism. At each
threshold of joint p-values, we obtain a list of prioritized
mechanisms for RFS prognosis. Individual FAIME-derived
predictors of survival are identified according to a significance
threshold of adjusted-p,0.05 after controlling the Stouffer meta-
analysis for multiple comparisons using the conservative Bonfer-
roni adjustment (Cox Proportional Hazard applied to datasets E
and then F, taking into account the direction of the association for
the sign of the Stouffer Z score).
As a validation, the gene members of significant RFS genes are
extracted to conduct the principal component analysis. For each
mechanism, the resultant 1
st component is compared with FAIME
Scores for the RFS prognosis analysis. Bioconductor package amap
is employed to run the PCA analysis and the values of the resultant
1st component are compared with FAIME Scores for each patient
in dataset E and F. Two types of analyses are conducted: 1) the
non-parametric Spearman correlation is calculated between 1
st
component values and FAIME Scores across all samples, and 2)
the Cox regression analyses of RFS are conducted for both
individual FAIME Scores and 1st component values for each
sample. Note that for the patient with duplicate measured samples
in dataset E, we use the mean expression value to represent its
expression measurement and genes with non-measurable expres-
sion values are assigned to a value of zero in Dataset F.
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